Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registry - PubMed
6 hours ago
- #Comparative Effectiveness
- #Late-Onset Multiple Sclerosis
- #Real-World Evidence
- The study compared anti-CD20 therapies (like ocrelizumab) and S1P receptor modulators (like fingolimod) in late-onset multiple sclerosis (LOMS), defined as symptom onset after age 50.
- Using real-world data from the MSBase registry (347 patients), no significant differences were found in annualized relapse rate, disability progression, or progression independent of relapse activity between the two treatment groups.
- Exploratory analyses suggested anti-CD20 therapies might offer better outcomes in specific subgroups: patients younger than 55, with shorter disease duration (≤2 years from diagnosis), and lower disability (EDSS < 3).